secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0000105770-23-000064
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q3: adj EPS $2.16, rev $747.4M; raises FY adj EPS outlook to $7.95-8.00
--------------------------------------------------------------------------------

- Q3 net sales $747.4M, +8.8% YoY; organic growth 5.7%.
- Reported diluted EPS $2.14 (+34.6%); adjusted diluted EPS $2.16 (+6.4%).
- FY2023 net sales guidance cut to $2.950-2.960B (from $2.970-2.995B); organic growth now 2-3%.
- FY2023 adjusted EPS guidance raised to $7.95-8.00 (from $7.65-7.80); dividend increased to $0.20/share (+5.3%).
- Proprietary Products net sales +6.3% (organic +3.2%); Contract-Mfg +20.8% (organic +17.4%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577023000064/0000105770-23-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577023000064/wst-20231026.htm
  HTML page:      https://secwatch.observer/filing/0000105770-23-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer